PDC-APB / Hapten Sci - LARVOL DELTA

A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: Hapten Sciences, Inc.; Trial completion date: Jun 2022 ➔ Dec 2022; Initiation date: Jul 2021 ➔ Nov 2021; Trial primary completion date: May 2022 ➔ Nov 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Contact Dermatitis • Dermatitis • Dermatology • Immunology

A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: Hapten Sciences, Inc.

New P1 trial • Contact Dermatitis • Dermatitis • Dermatology • Immunology